Lipid-assisted PEG-<i>b</i>-PLA nanoparticles with ultrahigh SN38 loading capability for efficient cancer therapy-Reference-Cited by-同舟云学术

Lipid-assisted PEG-b-PLA nanoparticles with ultrahigh SN38 loading capability for efficient cancer therapy

Published:2023 Issue:22 Volume:11 Page:7445-7457
ISSN:2047-4830
Container-title:Biomaterials Science
language:en
Short-container-title:Biomater. Sci.

Author:

Huang Xiaoyi¹,Li Jieyi¹,Yang Yanfang¹,Wang Zi-Lu²,Yang Xian-Zhu¹³⁴^ORCID,Lu Zi-Dong²,Xu Cong-Fei¹³⁵^ORCID

Affiliation:

1. School of Biomedical Sciences and Engineering, South China University of Technology, Guangzhou International Campus, Guangzhou 511442, P.R. China

2. School of Medicine, South China University of Technology, Guangzhou 510006, P.R. China

3. National Engineering Research Center for Tissue Restoration and Reconstruction, South China University of Technology, Guangzhou 510006, P.R. China

4. Guangdong Provincial Key Laboratory of Biomedical Engineering, South China University of Technology, Guangzhou 510006, P.R. China

5. Key Laboratory of Biomedical Materials and Engineering of the Ministry of Education, South China University of Technology, Guangzhou 510006, P.R. China

Abstract

Lipid-assisted PEG-b-PLA nanoparticles achieve stable and ultrahigh SN38 entrapment through attenuating intermolecular π–π stacking of SN38 for efficient cancer therapy.

Funder

Guangzhou Municipal Science and Technology Project

Basic and Applied Basic Research Foundation of Guangdong Province

Fundamental Research Funds for the Central Universities

National Natural Science Foundation of China

National Key Research and Development Program of China

Publisher

Royal Society of Chemistry (RSC)

Subject

General Materials Science,Biomedical Engineering

Link

http://pubs.rsc.org/en/content/articlepdf/2023/BM/D3BM01469J

Reference47 articles.

1. Targeting Topoisomerase I in the Era of Precision Medicine

2. Targeting neddylation sensitizes colorectal cancer to topoisomerase I inhibitors by inactivating the DCAF13-CRL4 ubiquitin ligase complex

3. Topoisomerase I inhibitors: camptothecins and beyond

4. Individualization of Irinotecan Treatment: A Review of Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics

5. Advances in delivery of Irinotecan (CPT-11) active metabolite 7-ethyl-10-hydroxycamptothecin